Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Office of Research & Development

print icon sign up for VA Research updates

Funded Project Details - FY2021




Project Number:

I01BX004751-01
Title: Regulation of Targeted Therapeutic Response by the Immune Microenvironment in HNSCC
Principal Investigator:

Lynn Heasley

Location: Denver, CO
Congressional District Code: 6
Research Service: Biomedical Laboratory R&D
Project Period: July 2019 - June 2023
FY 2021 Funding Amount: $250,322
Total Award Amount
(all years):
$1,146,931
Abstract: View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER


Excerpt:

Despite optimized therapeutic regimens, the 5-year survival rate for head and neck squamous cell carcinoma (HNSCC) remains around 50%. EGFR is a key component of a receptor tyrosine kinase (RTK) network that functions as a non-mutated “driver” in HNSCC cell lines and is the target for the FDA-approved agent, cetuximab. Individually, HNSCC patients exhibit wide-ranging extent of response to cetuximab as well as ERBB family- targeted tyrosine kinase inhibitors (TKIs) such as afatinib. Importantly,...



Questions about the R&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.